111
Participants
Start Date
October 19, 2020
Primary Completion Date
November 20, 2023
Study Completion Date
October 21, 2024
Ofatumumab
Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
Ms Ctr Of Northeastern Ny, Latham
International Neurorehab Institute, Lutherville
AMO Corporation, Tallahassee
Infinity Clinical Research LLC, Hollywood
University Of South Florida, Tampa
Alabama Neurology Associates PC, Birmingham
Sibyl Wray MD Neurology PC, Knoxville
Columbus Neuroscience, Westerville
Parkland Health and Hospital Systems, Dallas
Central TX Neuro Consultants P A, Round Rock
UC Health Neuroscience Ctr, Aurora
Ctr for Neurology and Spine, Phoenix
Cleveland Clinic Foundation, Las Vegas
Neuro Center, Pomona
Swedish Neuroscience Institute, Seattle
Dana Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Cente, Boston
Neurology Center of New England PC, Foxborough
Dragonfly Research LLC, Wellesley
Caribbean Center for Clinical Research, Inc, Guaynabo
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY